On April 20, 2026, the Federal Register published notice FR Doc. 2026-07615. The title is bureaucratic: "Potential New Indication for Testosterone Replacement Therapy." The implications are not.
"Holders of currently approved TRT NDAs interested in seeking approval for the treatment of low libido in men with decreased libido associated with idiopathic hypogonadism are encouraged to contact FDA by April 30, 2026, for further information regarding submission of a supplemental NDA, including data needed to support the new indication."
— Federal Register, Vol. 91, April 20, 2026
Read that sentence carefully. The FDA is asking manufacturers of approved testosterone products — gels, patches, injectables — to pursue expanding their labels to cover men whose low testosterone has no identifiable structural or genetic cause. This is the category currently excluded from every approved testosterone indication in the United States. It is also, by every available estimate, the majority of men with clinically low testosterone.
This notice did not arrive in isolation. It is the most visible point of a triangle formed by three simultaneous federal actions that, taken together, are reshaping who gets treated, how they access treatment, and on what diagnostic basis — except that last part hasn't actually been resolved.
The Three Sides
Federal Register notice invites sponsors to pursue new indication for idiopathic hypogonadism with low libido. Expert panel (Dec 2025) recommended expanding beyond structural/genetic causes, removing prostate cancer contraindication, and descheduling testosterone from Schedule III.
Fourth temporary extension of COVID-era telehealth flexibilities runs through December 31, 2026. Permanent framework proposed (Jan 2025 NPRM) but not finalized. If the rule lapses, 1.66 million patients who access testosterone via telehealth face in-person requirements overnight.
Nine major guidelines. Nine different testosterone thresholds (264–350 ng/dL). Up to 130% inter-laboratory variability for the same blood sample. 30% of men diagnosed as low normalize on retest. No guideline body has resolved this. None is attempting to.
The FDA is widening the door. The DEA is keeping the telehealth hallway open. And nobody has agreed on what the room looks like — how to reliably determine which men walking through that door actually have the condition being expanded.
What the Expert Panel Actually Said
The December 10, 2025 meeting wasn't an FDA advisory committee — it was an expert panel convened outside the formal advisory process, which means different conflict-of-interest disclosure standards. The nine presenters included Abraham Morgentaler (Harvard), Mohit Khera (Baylor, co-moderator), Martin Miner (Brown), Aaron Bernie (Indiana), Sandeep Dhindsa (SLU), Adrian Dobs (Johns Hopkins), Richard Iorio (FDA Principal Medical Advisor), ADM Brian Christine (HHS ASH), and Shalin Shah (CEO of Marius Pharmaceuticals, maker of Kyzatrex, an oral testosterone product).
The panel's recommendations went further than the Federal Register notice suggests:
What the panel did not discuss: specific diagnostic thresholds. How to distinguish idiopathic hypogonadism from normal aging. How to harmonize the 130% inter-laboratory variability that makes any threshold unreliable. The structural foundation on which the entire expansion would rest — left unaddressed.
The Market Responded Before the Infrastructure Question Was Asked
Between April 16 and 17, 2026, Hims & Hers Health (HIMS) gained 25% in two trading sessions. Volume hit 74.6 million shares — 111% above its three-month average. Bank of America raised its price target. The company had already launched branded oral testosterone (Kyzatrex) and compounded enclomiphene through its telehealth platform.
The market priced in the expansion before anyone asked: expand based on what diagnostic criteria?
This is not theoretical. In 2022, Dubin et al. published in JAMA Internal Medicine the results of a secret-shopper study of seven DTC testosterone platforms. Of those platforms, 85.7% offered testosterone to a man with a level of 675 ng/dL — unambiguously normal by every guideline. 85.7% had no testosterone threshold for initiating treatment. 83.3% didn't discuss polycythemia risk. Wider indication plus easier access plus absent diagnostic guardrails is not a hypothetical scenario. It is the current trajectory.
The Telehealth Clock
The DEA's fourth temporary extension of COVID-era telehealth flexibilities expires December 31, 2026. A proposed permanent rule (January 2025 NPRM) would create a lasting framework with PDMP checks, identity verification, and new registration requirements. It has not been finalized.
If it is not finalized before the extension expires, the default reverts to pre-COVID rules: in-person evaluation required before prescribing any Schedule III substance, including testosterone. Selinger and Thallapureddy (PLOS ONE, 2024) documented 1.66 million patients filling testosterone prescriptions in 2022, with 120% growth among men under 24. The telehealth share of that total is not precisely known, but the DTC industry's growth coincides exactly with the telehealth extension period.
The irony: the expert panel recommended descheduling testosterone from Schedule III. If enacted, this would collapse the DEA telehealth issue entirely — no controlled substance, no in-person requirement. But descheduling testosterone is politically complex when the PDMP data shows the fastest prescription growth is in men under 24, and anabolic steroid abuse remains a distinct regulatory concern.
Timeline of Convergence
| Date | Event | Agency |
|---|---|---|
| Feb 2025 | FDA removes cardiovascular black box warning from TRT | FDA |
| Dec 2025 | Expert panel recommends expanded indication, descheduling, prostate contraindication removal | FDA |
| Dec 31, 2025 | Fourth temporary telehealth extension issued (through Dec 31, 2026) | DEA/HHS |
| Feb 6, 2026 | Endocrine Society submits comments to FDA on TRT expansion | Professional |
| Apr 16, 2026 | FDA announcement: encouraging sponsors to pursue idiopathic HH indication | FDA |
| Apr 16-17, 2026 | HIMS stock +25% in two sessions; DTC sector repriced upward | Market |
| Apr 20, 2026 | Federal Register publishes FR Doc. 2026-07615 | FDA |
| Apr 30, 2026 | Deadline for NDA holders to contact FDA about supplemental applications | FDA |
| Dec 31, 2026 | Telehealth extension expires. Permanent rule may or may not be finalized. | DEA |
The Missing Side
The triangle's third side — diagnostic infrastructure — is the one nobody is building. Here is what exists:
| Guideline Body | Threshold (ng/dL) | Year |
|---|---|---|
| Endocrine Society | 264 | 2018 |
| AUA | 300 | 2018 |
| EAU | 264 | 2023 |
| BSSM/BES | 231 (definite) / 345 (gray zone) | 2022 |
| ISSM/ICSM | 350 | 2024 |
| FDA (FR 2026-07615) | Not specified | 2026 |
A man with a testosterone level of 280 ng/dL is definitively hypogonadal by AUA and ICSM criteria, in the gray zone by BSSM standards, and above the Endocrine Society threshold. The same blood sample sent to two different labs using different immunoassay platforms can return values that differ by 130%, per CDC Hormone Standardization (HoSt) Program data. The CDC has been working on assay harmonization since 2007. Participation is voluntary. Not all clinical labs use mass spectrometry.
The Federal Register notice does not specify a diagnostic threshold for the new indication. It asks manufacturers to bring their own data. This means each supplemental NDA could propose a different threshold, evaluated by the same agency that could not harmonize the existing ones.
What This Actually Means
I wrote in "The Mirror" that the same broken diagnostic system produces simultaneous under-diagnosis (5% treatment rate among hypogonadal men) and over-diagnosis (40% of treated men lacking documented deficiency). The triangle is the mirror scaled to federal policy.
The structural problem:
The FDA is expanding who can be treated for a condition whose diagnostic boundary no two guidelines agree on, delivered through a telehealth channel that may or may not exist in eight months, prescribed based on a laboratory measurement that varies up to 130% between platforms. Each piece of the triangle assumes the other two are resolved. None of them are.
This is not an argument against expanding access. The evidence from TRAVERSE (HR 0.73 for MACE, n=5,246) removed the cardiovascular safety concern that constrained prescribing for a decade. Men with genuine idiopathic hypogonadism and disabling symptoms deserve treatment options. The December panel's observation that TRT has been artificially restricted to a narrow diagnostic category since the 1990s is defensible.
But expanding indication without fixing diagnosis is like widening a highway while the traffic lights are broken. More cars will get through. Whether they're going to the right destination depends entirely on infrastructure that doesn't exist yet.
What I'm Watching
Three things will determine whether the triangle resolves or collapses:
This article builds directly on "The Mirror" (#39), which documented the diagnostic paradox at clinical level, and "The Exit" (#38), which mapped the structural gaps in evidence production. "The Triangle" traces those same patterns upward — from clinical measurement to federal policy. The system fails at every level for the same reason: it builds capacity before it builds infrastructure.